SCHEMBL6794653

SCHEMBL6794653

Cc1ccc(S(=O)(=O)OCCc2csc(N(C)C(=O)OC(C)(C)C)n2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMD10 O75832 1/20 0.35
MAPT P10636 2/20 0.34
LMNA P02545 1/20 0.34
F2 P00734 2/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
ALDH1A1 P00352 2/20 0.34
GPR119 Q8TDV5 1/20 0.34
GRM1 Q13255 1/20 0.33
ADRB2 P07550 1/20 0.33
ADRB1 P08588 1/20 0.33
ADRB3 P13945 1/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
TP53 P04637 1/20 0.32
NR1D1 P20393 1/20 0.32
KDM4E B2RXH2 1/20 0.32
STAT3 P40763 1/20 0.32
MAPK14 Q16539 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6800933 0.80 SIRT1 (0.44) MAPTLMNAMEN1KMT2ASMN1; SMN2
SCHEMBL28302436 0.77 MEN1 (0.40) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL7083749 0.77 MAPK14 (0.40) PSMD10MAPTLMNAMEN1KMT2A
SCHEMBL6794742 0.77 MEN1 (0.40) MAPTLMNAMEN1KMT2ANPC1
SCHEMBL6800670 0.75 KMT2A (0.56) MAPTLMNAMEN1KMT2ASMN1; SMN2
SCHEMBL6966988 0.73 F2 (0.42) F2MEN1KMT2AALDH1A1
SCHEMBL28302432 0.73 MEN1 (0.45) MAPTLMNAMEN1KMT2ASMN1; SMN2
SCHEMBL1649505 0.73 F2 (0.40) PSMD10F2MEN1KMT2AALDH1A1
SCHEMBL27583367 0.73 KMT2A (0.41) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL30830665 0.73 PSMD10 (0.39) PSMD10MAPTLMNAF2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US disclosed
EP-1326835-A1 BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-07-16 EP disclosed
WO-2002028835-A1 BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 PSMD10 905/4885MAPT 4795/4885LMNA 1239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.